The biotech industry continued to outpace the broader markets in July as a number of companies reported major news that have sent shares soaring. The iShares NASDAQ Biotechnology Index ETF (IBB) has gained over 13 percent in the past month, more than triple the 3.9 percent gain posted by the Dow Jones over the same period. Recent programs introduced by the FDA designed to speed up the approval process and improve communication channels with biotech companies have provided a major confidence boost for the industry The FDA has approved a total of 14 new drugs in 2013, new drug approvals reached a 15-year high in 2012 (39).
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) shares traded in the range of $44.76 to $45.92 Tuesday before settling to close at $45.74, an increase of 2.28 percent. The stock appears to be facing some resistance at the $46.94 and $50.37 levels with some support at $45.27. Shares of Alnylam Pharmaceuticals have gained approximately 150.0 percent year-to-date.
More information on Alnylam Pharmaceuticals and access to the free equity report can be found at:
www.WallStreetFundamentals.com/ALNY
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) shares traded in the range of $3.87 to $4.40 Tuesday before settling to close at $3.98, a decrease of 9.13 percent. The stock appears to be facing some resistance at $4.58 with some support at the $2.81 and $2.02 levels. Shares of BioCryst Pharmaceuticals have gained over 150.0 percent in the past month.
More information on BioCryst Pharmaceuticals and access to the free equity report can be found at:
www.WallStreetFundamentals.com/BCRX
InterMune Inc. (NASDAQ: ITMN) shares traded in the range of $14.77 to $15.23 Tuesday before settling to close at $15.22, an increase of 2.70 percent. The stock appears to have some support at the $14.74, $11.36 and $10.58 levels. Shares of InterMune have gained approximately 57.0 percent year-to-date.
More information on InterMune and access to the free equity report can be found at:
www.WallStreetFundamentals.com/ITMN
Sarepta Therapeutics Inc. (NASDAQ: SRPT) shares traded in the range of $34.20 to $35.88 Tuesday before settling to close at $35.21, an increase 0.28 percent. The stock appears to be facing some resistance at the $37.07 and $39.93 levels with some support at $34.59. Shares of Sarepta Therapeutics have gained over 36.0 percent year-to-date.
More information on Sarepta Therapeutics and access to the free equity report can be found at:
www.WallStreetFundamentals.com/SRPT
Wall Street Fundamentals offers our members a full range of investor services including in-depth equity reports on your favorite companies and timely market updates featuring the hottest stocks trending in the marketplace.
Activate your always free membership by signing up at www.WallStreetFundamentals.com today.
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Wall Street Fundamentals has no financial relationship with any company whose stock is mentioned in this release.
Contact:
Wall Street Fundamentals
Website: www.WallStreetFundamentals.com
Email: editor@wallstreetfundamentals.com